VERTEX PHARMACEUTICALS INC / MA Intangible Assets, Net (Excluding Goodwill)
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Intangible Assets, Net (Excluding Goodwill) of $412.80 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-04
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $412.80M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $418.50M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $424.20M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $429.80M.
| Period end | Intangible Assets, Net (Excluding Goodwill) |
|---|---|
| 2026-06-30 | $412.80M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $418.50M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $424.20M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $429.80M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $435.50M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $441.20M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $825.90M 10-K · filed 2026-02-13 |
| 2024-09-30 | $831.60M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $837.50M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $834.90M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $839.90M 10-K · filed 2025-02-13 |
| 2023-09-30 | $603.60M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $603.60M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $603.60M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $603.60M 10-K · filed 2024-02-15 |
| 2022-09-30 | $603.60M 10-Q · filed 2022-10-28 |
| 2022-06-30 | $387.00M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $400.00M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $400.00M 10-K · filed 2023-02-10 |
| 2021-09-30 | $400.00M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $400.00M 10-Q · filed 2021-07-30 |
| 2021-03-31 | $400.00M 10-Q · filed 2021-04-30 |
| 2020-12-31 | $400.00M 10-K · filed 2022-02-09 |
| 2020-09-30 | $400.00M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $400.00M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $400.00M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $400.00M 10-K · filed 2021-02-11 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |